clinical_trials
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
Confidence88·multiple reportsImportance90NP-EVT-20261112-CCFF730
Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.
Read the original at the primary source
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
Adam Feuerstein · 11/12/2026, 11:30:00 AM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —